Pfizer on May 29, 2026, reported that its LORBRENA CROWN trial in advanced non-small cell lung cancer (NSCLC) achieved the longest progression-free survival (PFS) to date—22.9 months—marking a potential shift …
@2025 – Hosted by ByoHosting – Most Recommendeed Webhhosting. For complains, abuse, advertising contact: office@byohosting.com